ATE265215T1 - Dexrazoxan zur behandlung von unerwünschter extravasation von anthrazyklinen - Google Patents

Dexrazoxan zur behandlung von unerwünschter extravasation von anthrazyklinen

Info

Publication number: ATE265215T1
Authority: AT; Austria
Prior art keywords: treatment; extravasation; anthrazyclines; dexrazoxane; adverse
Prior art date: 1999-03-12

Application number

AT00910564T

Other languages

English (en)

Inventor

Seppo W Langer

Peter Buhl Jensen

Maxwell Sehested

Original Assignee

Antianthra Aps

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-12

Filing date

2000-03-13

Publication date

2004-05-15

2000-03-13 Application filed by Antianthra Aps filed Critical Antianthra Aps

2004-05-15 Application granted granted Critical

2004-05-15 Publication of ATE265215T1 publication Critical patent/ATE265215T1/de

Links

206010015866 Extravasation Diseases 0.000 title abstract 4
230000036251 extravasation Effects 0.000 title abstract 4
238000011282 treatment Methods 0.000 title abstract 4
BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 title abstract 2
230000002411 adverse Effects 0.000 title 1
229960000605 dexrazoxane Drugs 0.000 title 1
239000002574 poison Substances 0.000 abstract 3
231100000614 poison Toxicity 0.000 abstract 3
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 2
108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 2
229940045799 anthracyclines and related substance Drugs 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 abstract 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 abstract 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 abstract 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 abstract 1
101710183280 Topoisomerase Proteins 0.000 abstract 1
230000003197 catalytic effect Effects 0.000 abstract 1
229960000975 daunorubicin Drugs 0.000 abstract 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
229960004679 doxorubicin Drugs 0.000 abstract 1
229960001904 epirubicin Drugs 0.000 abstract 1
229960000908 idarubicin Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000011458 pharmacological treatment Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Chemical And Physical Treatments For Wood And The Like (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT00910564T 1999-03-12 2000-03-13 Dexrazoxan zur behandlung von unerwünschter extravasation von anthrazyklinen ATE265215T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199900355		1999-03-12
PCT/DK2000/000107 WO2000054782A1 (en)	1999-03-12	2000-03-13	Treatment of accidental extravasation of anthracyclines

Publications (1)

Publication Number	Publication Date
ATE265215T1 true ATE265215T1 (de)	2004-05-15

Family

ID=8092594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00910564T ATE265215T1 (de)	1999-03-12	2000-03-13	Dexrazoxan zur behandlung von unerwünschter extravasation von anthrazyklinen

Country Status (17)

Country	Link
US (1)	US6727253B2 (de)
EP (2)	EP1162981B1 (de)
JP (1)	JP4422916B2 (de)
CN (1)	CN1199644C (de)
AT (1)	ATE265215T1 (de)
AU (1)	AU769533B2 (de)
BR (1)	BR0009473A (de)
CA (1)	CA2367240C (de)
DE (2)	DE1162981T1 (de)
DK (1)	DK1162981T3 (de)
ES (1)	ES2220424T3 (de)
HK (1)	HK1043054B (de)
MX (1)	MXPA01009212A (de)
NO (1)	NO327354B1 (de)
PT (1)	PT1162981E (de)
RU (1)	RU2252761C2 (de)
WO (1)	WO2000054782A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60209471D1 (de) *	2001-03-29	2006-04-27	Topo Target As Copenhagen Koeb	Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii
WO2007062076A2 (en) *	2005-11-23	2007-05-31	Novartis Ag	Dexrazoxane formulations and methods
US11633487B2 (en) *	2014-08-06	2023-04-25	Ascendis Pharma A/S	Prodrugs comprising an aminoalkyl glycine linker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4963551A (en) *	1987-12-21	1990-10-16	Erbamont Inc.	Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof
US5242901A (en) *	1988-01-27	1993-09-07	New York University	Reduction of anthracycline induced cardiotoxicity
GB9122720D0 (en) *	1991-10-25	1991-12-11	Holthuis Josephus J M	(s)(+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)formulations and their preparation
WO1993021938A1 (en) *	1992-05-04	1993-11-11	Adria Laboratories	Methods for treating cancer using high-dose epirubicin
EP0642353A1 (de)	1992-05-14	1995-03-15	Oncologix, Inc.	Behandlung des vaskularen permeabilitätssyndroms und der kollagenase induzierten krankheit durch administrieren von inhibitoren der matrix-metalloproteinase(20.01.94)
US5620961A (en) *	1994-04-25	1997-04-15	Markovic; Nenad S.	Fructose ester-β-cyclodextrin complexes and processes for making and using same
EP0874630B1 (de) *	1996-01-11	2003-08-20	TopoTarget ApS	Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
FR2758264B1 (fr)	1997-01-16	1999-03-26	Charles Dumontet	Compositions medicamenteuses contenant de l'edta ou un de ses derives pour la prevention de la toxicite cutanee et sous-cutanee des anthracyclines et de leurs derives
WO1998041202A1 (en)	1997-03-20	1998-09-24	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Hydroxybenzoate metabolites and hydroxybenzoate analogues as protectors against oxidative stress and chemotherapeutic drug cytotoxicity, cardiotoxicity and extravasation tissue injury

2000
- 2000-03-13 AT AT00910564T patent/ATE265215T1/de active
- 2000-03-13 RU RU2001127663/15A patent/RU2252761C2/ru active
- 2000-03-13 DE DE1162981T patent/DE1162981T1/de active Pending
- 2000-03-13 EP EP00910564A patent/EP1162981B1/de not_active Expired - Lifetime
- 2000-03-13 CN CNB00806167XA patent/CN1199644C/zh not_active Expired - Lifetime
- 2000-03-13 AU AU32726/00A patent/AU769533B2/en not_active Expired
- 2000-03-13 HK HK02104568.2A patent/HK1043054B/en not_active IP Right Cessation
- 2000-03-13 JP JP2000604858A patent/JP4422916B2/ja not_active Expired - Fee Related
- 2000-03-13 CA CA2367240A patent/CA2367240C/en not_active Expired - Lifetime
- 2000-03-13 PT PT00910564T patent/PT1162981E/pt unknown
- 2000-03-13 DE DE2000610241 patent/DE60010241T2/de not_active Expired - Lifetime
- 2000-03-13 MX MXPA01009212A patent/MXPA01009212A/es active IP Right Grant
- 2000-03-13 WO PCT/DK2000/000107 patent/WO2000054782A1/en not_active Ceased
- 2000-03-13 BR BR0009473-0A patent/BR0009473A/pt not_active Application Discontinuation
- 2000-03-13 ES ES00910564T patent/ES2220424T3/es not_active Expired - Lifetime
- 2000-03-13 DK DK00910564T patent/DK1162981T3/da active
- 2000-03-13 EP EP04076271A patent/EP1459752A3/de not_active Withdrawn
2001
- 2001-06-29 US US09/893,521 patent/US6727253B2/en not_active Expired - Lifetime
- 2001-09-12 NO NO20014433A patent/NO327354B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2367240C (en)	2010-11-16
EP1459752A3 (de)	2007-07-18
JP4422916B2 (ja)	2010-03-03
NO327354B1 (no)	2009-06-15
DE60010241D1 (de)	2004-06-03
PT1162981E (pt)	2004-09-30
HK1043054B (en)	2004-12-17
EP1162981A1 (de)	2001-12-19
CN1199644C (zh)	2005-05-04
DE1162981T1 (de)	2002-05-23
NO20014433D0 (no)	2001-09-12
EP1459752A2 (de)	2004-09-22
AU3272600A (en)	2000-10-04
AU769533B2 (en)	2004-01-29
RU2252761C2 (ru)	2005-05-27
MXPA01009212A (es)	2004-04-23
DK1162981T3 (da)	2004-08-16
WO2000054782A1 (en)	2000-09-21
BR0009473A (pt)	2001-11-27
CA2367240A1 (en)	2000-09-21
DE60010241T2 (de)	2005-01-13
EP1162981B1 (de)	2004-04-28
JP2002539168A (ja)	2002-11-19
US20020099057A1 (en)	2002-07-25
NO20014433L (no)	2001-11-06
HK1043054A1 (en)	2002-09-06
CN1346275A (zh)	2002-04-24
US6727253B2 (en)	2004-04-27
ES2220424T3 (es)	2004-12-16

Legal Events

Date

Code

Title

Description

2005-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1162981

Country of ref document: EP

Publication	Publication Date	Title
CA2436799A1 (en)	2002-08-01	Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
DK0841949T3 (da)	2006-08-21	Anvendelse af saccharid-konjugater
BR9813961A (pt)	2000-09-26	Metodo para remover sais biliares de um paciente, polimero de polidialilamina e seus sais, e seu uso.
CY1110426T1 (el)	2015-04-29	Συνδυασμοι dmxaa και αλλων αντικαρκινικων ουσιων
DE69937562D1 (de)	2007-12-27	Verbessertes angereichertes blutplättchen wundheilmittel
BR9908391A (pt)	2000-10-31	Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina
BR9812134A (pt)	2000-07-18	Composição farmacêutica para tratamento de dismenorréia e parto prematuro
WO2001041753A3 (en)	2002-09-12	Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
AR028959A1 (es)	2003-05-28	Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
ATE220918T1 (de)	2002-08-15	Matrixprotein enthaltende zusammensetzungen zur wundheilung
PT95212A (pt)	1991-05-22	Processo para a preparacao de uma composicao para uso topico para o tratamento da fragilidade capilar, contendo defibrotide
ATE265215T1 (de)	2004-05-15	Dexrazoxan zur behandlung von unerwünschter extravasation von anthrazyklinen
AU1556800A (en)	2000-06-13	Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
ES2130506T3 (es)	1999-07-01	Uso de 5-acil-1,4-dihidropiridinas para tratamiento de enfermedades del snc.
ATE78168T1 (de)	1992-08-15	Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.
WO2001016355A3 (de)	2001-08-30	In-vitro-testsystem für gamma-sekretase aus angereicherten-membranen
BR0016720A (pt)	2002-09-03	Uso de trimebutina para tratamento de dores
DE69008282D1 (de)	1994-05-26	Kaffeesäure-Derivate, deren Verwendung für medizinische Behandlungen und diese enthaltende pharmazeutische Zusammensetzungen.
BRPI0410507A (pt)	2006-06-20	combinação de substáncias ativas, uso de uma combinação de substáncias e processo para o tratamento do abuso do álcool e/ou da dependência de álcool
PT874630E (pt)	2004-01-30	Terapia combinada de um inibidor da topoisomerase ii e um derivado da bis-dioxipiperazina
BR0008454A (pt)	2002-01-29	Composição sinergìstica anti-tumoral
WO2001068661A3 (en)	2002-03-21	Crystalline alkycycline derivative
NO830234L (no)	1983-07-27	Daunorubicin- og doxorubicinanaloger, deres fremstilling og bruk.
WO2001005382A8 (en)	2001-04-12	Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
WO1999053052A3 (de)	2000-01-20	Srebp-2-defiziente zellinien